Insmed (INSM) – 2026 Analyst Expectations 1. Revenue Outlook (2026) Consensus expectations for 2026 reflect accelerating growth driven by the first full calendar year of Brensocatib commercialization plus continued ARIKAYCE expansion. A. Total Revenue Consensus range:...
20251211 portfolio Analysis
lire plus